9 research outputs found

    Analysis of a lattice square design and its use in bioassays.

    Full text link
    This dissertation deals with the analysis of an experimental design called the Lattice Square design and its use in estimating the relative potency of test preparations in parallel line bioassays. A Lattice Square is an incomplete two-way design and has the advantage of being able to eliminate two sources of variation simultaneously while keeping the block size from becoming too large. The row and column incidence matrices of the design have many interesting mathematical properties which are derived and described in this dissertation, which contribute to making the analysis more elegant. Under suitable conditions and assumptions, the estimates of treatment effects can be improved upon due to the use of recovery of inter-row and column information. The complete detail of the analysis of such designs are also derived in this dissertation and a numerical illustration of the use of this design in multiple bioassay is provided. Furthermore, this dissertation contains interesting and useful results and information about "BLUPs" (Best Linear Unbiased Predictors) of random row and column effects and "penalized least squares" equations and their advantages in the analysis of incomplete two-way designs.Ph.D.BiostatisticsUniversity of Michigan, Horace H. Rackham School of Graduate Studieshttp://deepblue.lib.umich.edu/bitstream/2027.42/104221/1/9501062.pdfDescription of 9501062.pdf : Restricted to UM users only

    DOSE ADJUSTMENT PRACTICES OF PEGINESATIDE VS. EPOETIN IN EMERALD 1 AND 2 PIVOTAL TRIALS

    Get PDF
    Peginesatide (P) is a synthetic, pegylated, peptide-based ESA approved for treatment of anemia due to chronic kidney disease in adult patients (pts) on dialysis. P demonstrated noninferiority to epoetin (E) in maintenance of Hb levels in hemodialysis (HD) pts in two Phase 3 randomized, active-controlled, open-label trials (EMERALD 1,2). A large dialysis organization (LDO) recently reported an ESA dose adjustment rate of 12.1/pt-year (Bond et al, ISPOR 2012). This post hoc analysis evaluated dosing practices for maintaining Hb with P vs E. Pooled data from the two trials compared P (1x monthly; N=1066) with E (1-3x wkly; N=542) in HD pts previously on stable doses of E. Hb was measured during screening, at baseline and wkly (evaluation period, wks 29-36) or every 2 wks (all other periods). Dose adjustments were not to be made more frequently than every 4 wks, unless required for safety purposes. Dose adjustments (defined as change >±20% from last dose) were evaluated during the titration (wks 0-28), evaluation, and long-term follow-up (LT, wks 36-52) periods. Dose postponements were defined as >35d for P; for E, they were >4d, 6d, or 9d for TIW, BIW, and QW, respectively. Across the entire study period, P doses were adjusted ∼3 times less frequently and held ∼8 times less than P (Table). P (per pt-year) E (per pt-year) E/P ratio Total Dose Adjustments 3.5 10.3 2.9 Dose Increases 1.7 5.3 3.0 Dose Decreases 1.8 5.0 2.8 Dost Postponements 0.6 5.0 8.3 Within each treatment arm, dose adjustment and postponement rates (including corresponding E/P ratios) were similar across titration, evaluation, and LT periods. E dose adjustment rate was similar to that of real world practice in an LDO. E doses were adjusted and held more frequently than P despite similar protocol specifications for dose alteration and Hb maintenance

    Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies

    No full text
    <p>Article full text</p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s40121-017-0162-1"><b>here</b>.</a></p> <p>Provide enhanced content for this article</p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p>Other enhanced features include, but are not limited to:</p> <ul> <li>Slide decks</li> <li>Videos and animations</li> <li>Audio abstracts</li> <li>Audio slides</li> </ul

    Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates

    No full text
    <p>Article full text</p> <p>The full text of this article can be found <b><a href="https://link.springer.com/article/10.1007/s40121-016-0133-y">here.</a></b></p> <p>Provide enhanced content for this article</p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p>Other enhanced features include, but are not limited to:</p> <ul> <li>Slide decks</li> <li>Videos and animations</li> <li>Audio abstracts</li> <li>Audio slides</li> </ul
    corecore